Does BlackRock own Polaris?
BlackRock does not own Regeneron Pharmaceuticals, as it is a publicly traded company owned by a wide range of institutional and individual shareholders. BlackRock is, however, the largest institutional shareholder of Regeneron, holding approximately 8.95 million shares, which accounts for about 8.6% of the company's outstanding shares. This position is managed by BlackRock as part of its fiduciary duties for various investment funds and portfolios, meaning it holds these shares on behalf of its clients rather than as an owner-operator. Because Regeneron is a public entity, it operates independently under its own board of directors and executive management team, who are responsible for all strategic and operational decisions. BlackRock's significant stake grants it considerable voting power in corporate governance, but it does not confer direct control over the company's research, drug development, or commercial business activities.
Related FAQs
Polestar Automotive Holding UK PLC does not distribute cash dividends to its equity investors.
Executive compensation for Peter D. Arvan, serving as the President and Chief Executive Officer of Pool Corporation (POOLCORP), reflects leadership in the wholesale distribution of swimming pool supplies and outdoor living products.